Kornimate/medical-research-clean huggingface dataset:
fecal microbiota transplantation as a treatment for ulcerative colitis

Conditions: Ulcerative Colitis

Summary: ulcerative colitis (uc) is characterized by a disrupted homeostasis of the commensal bacterial population (dysbiosis). a promising therapy for restoration of the altered balance of the enteric microbiota is fecal microbial transplantation (fmt). fmt will ameliorate colitis via alterations of patients' microbiota and their proteolytic-dependent effect on epithelial permeability. design: 80 patients will undergo 1:1 randomization for multiple fmt (fecal microbiota transplantation) from a healthy donor or autologous (placebo) through colonoscopy and rectal enemas. the treating physicians and the patients will be blinded for the treatment arm. at the fmt visit (first week), blood and stool samples will be taken and patients will be filling out questionnaires to assess disease activity level. every 2 weeks patients will come to a clinic for a follow up visit. 8 weeks after fmt, patients will undergo sigmoidoscopy to assess disease severity, biopsies will be taken as well.


Eligibility criteria:
inclusion criteria: * over 3 month diagnosis of ulcerative colitis * active colitis disease with endoscopic score \>0 * ability to sign an informed consent exclusion criteria: * acute neutrophilia (under 500 neutrophils) * clostridium difficile infection * exposure to antibiotics 2 weeks prior to enrollment. * severe immune deficiency * hospitalization * proctitis involving less than 10cm of the rectum * malignancy with the past 5 years (excluding bcc) * an unstable dose of steroids or 5asa (5- aminosalicylic acid) with the past 2 weeks or of immunomodulators or biologic therapy within the past 12 weeks

Keywords: microbiota ulcerative colitis
effect of prayer on conditioned pain modulation and on pain intensity in healthy religious university students

Conditions: Healthy Subjects

Summary: with this study the investigators wish to examine the effect of prayer on pain intensity and on the conditioned pain modulation in healthy religious university students.

there has been a call for a model that incorporate spirituality in the biopsychosocial framework .the biopsychosocial- spiritual model recognizes the impact of the religious factors in modulating the biology of pain. the aim of this study is to measure the effect of praying as an intervention on conditioned pain modulation and on pain intensity. the investigators hypothesize that prayer would increase conditioned pain modulation compared to a no prayer control group in a healthy religious population. the investigators hypothesize that participants engaging in active prayer will show a higher increase in conditioned pain modulation compared to those engaging in passive prayer or no prayer. the present study is a randomized controlled trial comparing the effect of two types of prayer, the passive and the active prayer and no prayer, on conditioned pain modulation using the heat protocol and on pain intensity. participants are to be randomly assigned to 2 groups: the prayer group and the control group. the control group is of (n=50) participants and the prayer group is (n=150) participants to be divided according to the style of praying identified by the prayer function scale into active and passive prayer group. appropriate statistical analyses will be performed to evaluate and compare treatment effects.

Eligibility criteria:
inclusion criteria: * healthy female. * healthy male. * university students * religious participants who would score at least two over six on the non organizational religious activities subscale of the duke university religious index. exclusion criteria: * pregnant women. * individuals with chronic pain. * individuals with psychiatric disease. * individuals suffering from headache for more than 2 days a month. * individuals with high blood pressure. * individuals under regular use of medication. * individuals who would score 1 or 0 on the on the non organizational religious activities subscale of the duke university religious index.
contrast of buffered vs. unbuffered lidocaine in bone marrow biopsies

Conditions: Pain

Summary: oncology patients require numerous invasive procedures throughout their disease process including bone marrow biopsies (bmb). bmb.s are performed by a significant number of health care providers. one of the biggest concerns for health care providers is to improve patient comfort. the goal of this study was to reduce pain during bmbs. specific aims of the study were to determine if there is a difference in patients' perceived pain during injection of the pre-procedure anesthetic when buffered versus unbuffered lidocaine is administered to patient's receiving bone marrow biopsies. a double blind, experimental crossover design was used to examine the difference in pain levels when using buffered versus unbuffered lidocaine prior to the bilateral bone marrow biopsy procedure. based on a power analysis for a paired t-test, a convenience sample of 48 patients was enrolled into the study. patients served as their own control. the site of first biopsy, and which lidocaine solution was administered first, were randomized. a 100mm visual analogue scale (vas) was used to measure pain. all data has been collected, are currently under analysis, and results will be completed in august 2006. differences in groups will be examined using a paired t-test. a demographic questionnaire was used to gather select demographic variables. correlative studies will be done to examine the relationship between the patient's perceived pain scores and several exploratory variables. results of this study may change the current type of anesthetic used pre-bmbs thus improving patient comfort.


Eligibility criteria:
inclusion criteria: * any newly diagnosed patient at the arthur g. james cancer hospital and richard j. solove research institute whose hematologist or oncologist has ordered them to undergo a bilateral bone marrow biopsy for diagnostic and /or treatment purposes. * 18 years of age or older. exclusion criteria: * pregnant or lactating women. * patients with allergies to local anesthetics. * patients requiring a unilateral bone marrow biopsy. * patients that cannot lie flat in either the supine or prone position. * patients that have used any of the following: narcotics, non-narcotic analgesia or an anti-anxiolytic medication on the same calendar day as the scheduled procedure. these medications will not be given to the participant at any time before or during the procedure. * patients on long-acting narcotic medication. * patients with neuropathy in the posterior iliac crest area * patients with a platelet count less than 20,000. * patients who are cognitively impaired or unable to self-report pain using the vas. * patients with known bone metastasis.

Keywords: pain during injection of the pre-procedure anesthetic
sars-cov-2 /covid-19 admission screening in a university hospital setting

Conditions: Covid19; SARS-CoV-2

Summary: the proportion of asymptomatic carriers of sars-cov-2 remains elusive, so the potential benefit of systematic screening during the sars-cov-2-pandemic is controversial. we investigate the proportion of asymptomatic inpatients who were identified by systematic screening for sars-cov-2 upon hospital admission. adult patients admitted to the university hospital basel from 01.04.-14.06.2020 were routinely tested for sars-cov-2 within 72 hours of admission by nasopharyngeal swabs. each patient screened during the study period was retrospectively classified symptomatic or asymptomatic for covid-19 based on medical chart review.


Eligibility criteria:
inclusion criteria: * the patient population is defined as all adult patients hospitalized in the university hospital basel from april 1st, 2020 to june 14th, 2020. exclusion criteria: * outpatients * patients with sars-cov-2 screening in the outpatient test center * patients with a sars-cov-2 test more than 72 hours before hospital admission * test not performed (for any reason)

Keywords: screening asymptomatic
vdrive evaluation of remote steering and testing in lasso electrophysiology procedures study

Conditions: Atrial Fibrillation

Summary: this study will evaluate the use of a robotic device that is remotely controlled to maneuver a circular mapping catheter in the left atrium during atrial fibrillation (af) ablation procedures.

key to the success of an electrophysiology procedure is the ability to accurately map, sense and pace the heart. electrophysiology mapping catheters are available in a variety of shapes and electrode configurations. the majority of these catheters are manipulated manually by the physician. the vdrive simplifies these manipulations by allowing an operator to mechanically advance, retract, rotate, deflect and maneuver a circular mapping catheter. the circular mapping catheter is not altered in structure, function or indication in the same manner as the predicate device (cardiodrive catheter advancement system). this is a prospective, randomized, non-blinded, controlled study comparing manual navigation of a circular mapping catheter with mechanical navigation by the vdrive. a total of 120 patients are expected to complete the study: 80 patients in the vdrive navigation arm and 40 patients in the manual navigation arm. patients will be enrolled at a minimum of one site in the european union where the product is currently marketed and the united states, where the vdrive is considered to be investigational.

Eligibility criteria:
inclusion criteria: * left atrial af ablation procedure requiring the use of a lasso mapping catheter * subject must be at least 18 years of age * subject must be male, female of no childbearing potential, or a female that has a negative pregnancy test prior to randomization exclusion criteria: * unable to safely expose subject to a magnetic field * prior af ablation procedure * patients with fewer than 4 pvs are excluded * patients with persistent af in whom early recurrence of af following cardioversion would preclude completion of the pacing maneuvers described in the protocol or patients with other conditions that would similarly preclude completion of the pacing maneuvers * contraindication to procedure or unable to return for follow-up * history of clotting disorder, bleeding abnormalities or contraindication to anticoagulation * actively participating in other cardiac device trial(s) * currently pregnant * under 18 years of age * prosthetic valves * atrial abnormalities (thrombus, myxoma or baffle) * other exclusions per the investigator

Keywords: magnetic navigation robotic control rmt thermocool catheter
prolonged exposure versus treatment as usual in chronic posttraumatic stress disorder combat and terror related patients

Conditions: Posttraumatic Stress Disorder

Summary: assessing the efficacy of posttraumatic stress disorder (pe) treatment for chronic posttraumatic stress disorder (ptsd)


Eligibility criteria:
inclusion criteria: * ptsd exclusion criteria: * psychotic symptoms * dissociation * drug or alcohol dependence
platelet function on abacavir and tenofovir

Conditions: Cardiovascular Diseases; Platelet Aggregation, Spontaneous; HIV/AIDS

Summary: this is a small observational study aimed at observing differences in platelet function in hiv patients on abacavir versus tenofovir based anti-hiv drugs. there is some correlation between platelet activation and cardiovascular disease- this study will act as a pilot to see if platelet activation among abacavir users may explain the correlation between abacavir and cardiovascular disease in hiv positive patients. this study will enroll 44 participants total; 22 on abacavir-based treatment, 22 on tenofovir-based treatment. there is only one study visit which includes a blood draw, physical assessment, and review of medical history.


Eligibility criteria:
inclusion criteria: * hiv positive * stable antiretroviral regimen for \> 3months containing either abacavir or tenofovir * suppressed hiv viral load exclusion criteria: * current cigarette smoking * pre-existing platelet disorder * current or recent (last 6 months) antiplatelet therapy * pregnancy
echinocandins versus azoles for candidemia treatment

Conditions: Candidemia

Summary: candidemia is the most frequent invasive fungal disease in intensive care units (icus). it remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. successful clinical outcome requires early diagnosis and effective antifungal therapy. guidelines for the treatment of candidemia were published by the infectious diseases society of america (idsa) and the european society of clinical microbiology and infectious diseases (escmid). according to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. in this context, we are setting up a retrospective cohort study using hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.


Eligibility criteria:
inclusion criteria: * patients who had a diagnosis of candidemia during icu stay and were treated with echinocandins or azoles exclusion criteria: * patients with neutropenia * patients without antifungal treatment * patients who received antifungal therapy for more than two days before candidemia diagnosis * patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy * patients who received less than 4 days of antifungal therapy after candidemia diagnosis
qlaris phase 2 study of qls-111 in poag and/or oht patients

Conditions: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye; Ocular Hypertension (OHT)

Summary: qlaris' phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of qls-111 in primary open-angle glaucoma (poag) or ocular hypertension patients.

a randomized, active- and vehicle-controlled, multi-site, double-masked study to evaluate the safety and tolerability of qls-111 versus vehicle in subjects with primary open-angle glaucoma or ocular hypertension. primary objective is to evaluate the ocular and systemic safety and tolerability of 3 concentrations of qls-111 compared to vehicle control. secondary objective is to evaluate the ocular hypotensive efficacy of 3 concentrations of qls-111 with once daily morning (qam), once daily evening (qpm), and twice daily (bid) dosing versus vehicle with qam, qpm, and bid dosing.

Eligibility criteria:
inclusion criteria: * 18 years or older * able to provide written acknowledgement of giving informed consent * best corrected visual acuity (bcva) 20/200 or better bilateral poag or oht with documented historic iop value(s) ≥24 mmhg, in either eye * post-washout iop ≥22 mmhg in morning on visits 2 and 3 and ≥18 mmhg at noon on visit 2 exclusion criteria: * iop \>34 mmhg * severe glaucomatous damage that would preclude safe washout of prescribed ocular hypotensive medications * previous glaucoma surgery, certain procedures (trabeculotomy, shunt/tubes, cyclodestructive procedure) (selective laser trabeculoplasty (slt) allowed if done no earlier than 1 year from study, some minimally invasive glaucoma surgeries are allowed if done no earlier than 1 year from study) * ocular trauma, ocular infections, ocular inflammation, herpes simplex keratitis of eye * use of other ophthalmic concomitant medications during the study * uncontrolled hypertension or hypotension * significant systemic or psychiatric disease * participation in other investigational trial 30 days prior to screening or previous enrollment and treatment with qlaris investigational product * pregnant or lactating

Keywords: qlaris poag oht iop glaucoma osprey
mood and subthalamic nucleus (stn) deep brain stimulation

Conditions: Movement Disorders

Summary: the purpose of this research study is to investigate any changes seen in mood or behavior following deep brain stimulation for movement disorders.


Eligibility criteria:
inclusion criteria: * idiopathic pd diagnosed by a movement disorders neurologist * approved by a movement disorders neurologist as clinically needing a dbs device * absence of significant cognitive dysfunction (mattis dementia rating scale score of greater than or equal to 116) * mri without evidence of structural abnormality (stroke, tumor, malformation, etc) * no prior neurosurgical intervention exclusion criteria: * none

Keywords: staged versus simultaneous bilateral dbs
inhibition of plasma kallikrein as a new therapy for lung injury

Conditions: Lung Injury

Summary: phase 1 study investigating safety of lanadelumab administration to patients with lung injury

this study will investigate the safety of inhibition of plasma kallikrein by lanadelumab administration in patients with lung injury.

Eligibility criteria:
inclusion criteria: * age \>18 years admitted to the icu with primary diagnosis of lung injury. the criteria for the diagnosis of lung injury include five principal elements: hypoxemia (blood oxygen saturation (pao2) ≤92% when breathing ambient air, ratio of pao2 to the fraction of inspired oxygen (fio2) ≤300), diffuse pulmonary infiltrates on chest radiographs, decreased lung compliance, and the absence of congestive heart failure. * both males and females will be recruited in the proportion in which they are admitted to the icu with lung injury. * arterial cannula in place as part of usual care for the measurement of blood gases. * patients may or may not be intubated and mechanically ventilated. * able to provide informed consent, or if unable to do so, a responsible person: medical treatment decision maker is available (by telephone if necessary) who can be approached to seek consent. exclusion criteria: * other causes of lung infiltrates: pulmonary oedema, alveolar haemorrhage, adverse drug reactions, radiation injury and the idiopathic pneumonitis syndrome. * significant dysfunction of non-pulmonary organs in the opinion of the treating icu consultant. * death is deemed imminent or inevitable or there is underlying disease with a life expectancy of less than 90 days. * previously enrolled in this study. * enrolled in another study. * usually receives home oxygen. * usually receives any type of assisted ventilation at home. e.g. continuous positive airway pressure for obstructive sleep apnoea. * pregnant or might be pregnant. women aged 18 to 49 are excluded unless there is documented menopause, hysterectomy or surgical sterilisation, or a pregnancy test is negative. * objection from the treating clinician. * consent refused by the patient or substitute decision maker.
the johns hopkins heartburn center registry

Conditions: Gastroesophageal Reflux Disease; Barrett Esophagus; Laryngopharyngeal Reflux; Esophagitis

Summary: a multi-center, multi-year registry of patients with gastroesophageal reflux disease (gerd) undergoing diagnostic evaluation and/or treatment of gerd and associated diseases and complications.

this registry is a prospective, multicenter registry of patients undergoing diagnostic evaluation and/or treatment of gastroesophageal reflux disease and associated diseases and complications. patients who are eligible will have disease and therapy-specific data collected throughout treatment and long-term (5-year) follow-up. electronic data capture via redcap will be utilized for all sites.

Eligibility criteria:
inclusion criteria: * referred gerd patients willing to participate in long term follow-up (5 years) exclusion criteria: * potential participants will be excluded if unwilling or unable to complete surveillance questionnaires through this registry
the safety and efficiency of propranolol as an initial treatment for pediatric hemangioma

Conditions: Hemangioma

Summary: the purpose of this study is to determine the safety and efficiency of propranolol as an initial treatment for pediatric hemangioma.

* randomized (a group : propranolol, b group : prednisolone) * a group : 3 days admission and medication for 16 weeks * b group : medication for 16 weeks without admission * hemangioma volume comparison by using mri * other measurement and drug adverse reaction monitoring

Eligibility criteria:
inclusion criteria: * hemangioma patient ( 0 \~ 9 months old) * no treatment before * 10 \~ 20 % volume increase in 2 \~ 4 weeks * hemangioma that caused organ function * hemangioma that will cause aesthetic problem exclusion criteria: * cardiovascular disease (impossible to use propranolol) * drug adverse reaction or allergy history (propranolol, steroid) * bradycardia, atrioventricular block, atrial block * cardiogenic shock * right heart failure (pulmonary hypertension) * congestive heart failure * hypotension * peripheral nerve disease (moderate) * angina * hormone deficiency patient * pulmonary disease (asthma) * diabetic ketoacidosis * laser treatment history

Keywords: hemangioma propranolol prednisolone steroid
evaluation of social cognition in patient with type 1 or type 2 narcolepsy versus patients with idiopathic hypersomnia

Conditions: Narcolepsy; Social Cognition

Summary: narcolepsy is a chronic disabling neurologic disorder mainly characterised by excessive daytime sleepiness. type 1 narcolepsy is associated with a deficit of hypocretin in the cerebrospinal fluid responsible for the cataplexy symptom while type 2 shows a normal hypocretin level and no cataplexy. while the development of narcolepsy is independent of parental social level, narcolepsy has a significant influence on educational level, grading, social outcome, and welfare consequences. several studies assessed global cognition efficiency, mood, and attention in narcoleptic patients but only a few specifically measured social cognition and mostly without a control group. in a population of narcoleptics children, a severe impairment in social cognition is described for 20% of the group, contrary to 2 % for the control group. the literature also depicts some impairments in decision making, somatic and cognitive emotions responses but the emotion recognition seems to be preserved. a better understanding of the social and cognitive aspects of narcolepsy could lead to a better treatment of the disease in its entirety, including if relevant specific cognitive behavioural therapy. the protocol consists in a psychometric evaluation including several questionnaires in order to assess social cognition. it will be proposed to patients with type 1 or type 2 narcolepsy and patients with idiopathic hypersomnia.


Eligibility criteria:
inclusion criteria: * adult patients (\>/= 18years old) * diagnosis of type 1 or type 2 narcolepsy or idiopathic hypersomnia * non opposition exclusion criteria: * comorbid psychiatric or neurologic disease * patient under 18 years old * patient under guardianship, curators or deprived of liberty, refusal of the patient

Keywords: narcolepsy social cognition